Press release
Pulmonary Arterial Hypertension Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Acceleron, Liquidia Technologies, Pfizer, Merck, Insmed, Gossamer Bio, Johnson & Johnson, Nippon Shinyaku
"Pulmonary Arterial Hypertension Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pulmonary Arterial Hypertension Therapeutics Market.
The report provides a detailed description of the Pulmonary Arterial Hypertension drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Pulmonary Arterial Hypertension Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pulmonary Arterial Hypertension Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Pulmonary Arterial Hypertension therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Pulmonary Arterial Hypertension drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Pulmonary Arterial Hypertension treatment market.
Learn More about the Clinical and Commercial Development Activities in the Pulmonary Arterial Hypertension Therapeutics Domain:
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Pulmonary Arterial Hypertension Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Request for Sample PDF to Understand More About the Pulmonary Arterial Hypertension Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Pulmonary Arterial Hypertension Therapeutics Analysis
There are approx. 55+ key companies developing therapies for Pulmonary Arterial Hypertension. Currently, Liquidia Technologies is leading the therapeutics market with its Pulmonary Arterial Hypertension drug candidates in the most advanced stage of clinical development.
Pulmonary Arterial Hypertension Companies in the Therapeutics Market Include:
Pfizer, Eli Lilly and Company, United Therapeutics Corporation, Gilead Sciences, GSK, ICOS Corporation, Actelion Pharmaceuticals, Nippon Shinyaku, Bayer Group, Actelion Pharmaceuticals, Co Therix, Kaken Pharmaceutical, Sanofi-Aventis, Toray, Acceleron Pharma Inc., Altavant Sciences, Aerovate Therapeutics, Respira Therapeutics, Gossamer Bio Inc., Merck Sharp & Dohme Corp., Insmed Incorporated, Pharmaosa Biopharma Inc., Bial (Portela C S.A.), Liquida Technologies, Inc., Cereno Scientific AB, and others.
Emerging and Marketed Pulmonary Arterial Hypertension Therapies Covered in the Report Include:
• L606:Pharmaosa Biopharma Inc.
• LIQ861: Liquidia Technologies
• MK5475: Merck Sharp & Dohme Corp.
• Ralinepag: United Therapeutics
• REMODULIN/ TREPROST (treprostinil): United Therapeutics/ Mochida Pharmaceuticals
• RT234 (vardenafil inhalation powder): Respira Therapeutics
• Seralutinib (GB002): Gossamer Bio
• Sildenafil (Revatio): Pfizer
• Sotatercept (MK-7962): Merck
• Treprostinil Palmitil: Insmed Incorporated
• TYVASO (treprostinil): United Therapeutics
• UPTRAVI (selexipag): Johnson & Johnson/Nippon Shinyaku
And Many Others
Get an in-depth Assessment of the Emerging Therapies and Pulmonary Arterial Hypertension Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pulmonary Arterial Hypertension Current Treatment Patterns
4. Pulmonary Arterial Hypertension - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pulmonary Arterial Hypertension Late-Stage Products (Phase-III)
7. Pulmonary Arterial Hypertension Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pulmonary Arterial Hypertension Discontinued Products
13. Pulmonary Arterial Hypertension Product Profiles
14. Pulmonary Arterial Hypertension Companies
15. Pulmonary Arterial Hypertension Drugs
16. Dormant and Discontinued Products
17. Pulmonary Arterial Hypertension Unmet Needs
18. Pulmonary Arterial Hypertension Future Perspectives
19. Pulmonary Arterial Hypertension Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/pulmonary-arterial-hypertension-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight
Mucinous Cystic Neoplasms (MCNs) Market
https://www.delveinsight.com/report-store/mucinous-cystic-neoplasms-mcns-market
Overt Hepatic Encephalopathy Market
https://www.delveinsight.com/report-store/overt-hepatic-encephalopathy-market
Familial Hypercholesterolemia Market
https://www.delveinsight.com/report-store/familial-hypercholesterolemia-market-report
Lateral Epicondylitis (Tennis Elbow) Disease Market
https://www.delveinsight.com/report-store/lateral-epicondylitis-tennis-elbow-disease-market
Diverticulitis Market
https://www.delveinsight.com/report-store/diverticulitis-market
Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
Helicobacter Pylori Infections Market
https://www.delveinsight.com/report-store/helicobacter-pylori-infections-market
Charcot-Marie-Tooth Disease Market
https://www.delveinsight.com/report-store/charcot-marie-tooth-disease-market
Neurovascular Thrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Neurothrombectomy Devices Market
https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
Stargardt Disease (STGD) Market
https://www.delveinsight.com/report-store/stargardt-disease-stgd-market
Venous Leg Ulcer Market
https://www.delveinsight.com/report-store/venous-leg-ulcer-market
Genital Herpes Market
https://www.delveinsight.com/report-store/genital-herpes-market-forecast
Idiopathic Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/idiopathic-thrombocytopenic-purpura-market
Morquio Syndrome Market
https://www.delveinsight.com/report-store/morquio-syndrome-market
Lymphoedema Market
https://www.delveinsight.com/report-store/lymphoedema-market
Neurotrophic Keratopathy Market
https://www.delveinsight.com/report-store/neurotrophic-keratopathy-market
Oncolytic Virus Cancer Therapy Market
https://www.delveinsight.com/report-store/oncolytic-virus-cancer-therapy-market
Orthostatic Hypotension Market
https://www.delveinsight.com/report-store/orthostatic-hypotension-market
Advanced Wound Care (AWC) Market
https://www.delveinsight.com/report-store/advanced-wound-care-market
Opioid-related Disorders Market
https://www.delveinsight.com/report-store/opioid-related-disorders-market
Ankylosing Spondylitis (AS) Market
https://www.delveinsight.com/report-store/ankylosing-spondylitis-as-market
Chronic Insomnia Market
https://www.delveinsight.com/report-store/chronic-insomnia-market
Microscopic Polyangiitis (MPA) Market
https://www.delveinsight.com/report-store/microscopic-polyangiitis-mpa-market
Esophageal Squamous Carcinoma Market
https://www.delveinsight.com/report-store/esophageal-squamous-carcinoma-market
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market
Chemotherapy Induced Neutropenia (CIN) Market
https://www.delveinsight.com/report-store/chemotherapy-induced-neutropenia-cin-market
Idiopathic Interstitial Pneumonia Market
https://www.delveinsight.com/report-store/idiopathic-interstitial-pneumonia-market
Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
Dyslipidemia Market
https://www.delveinsight.com/report-store/dyslipidemia-market
Thymus Cancer Market
https://www.delveinsight.com/report-store/thymus-cancer-market
Tendonitis Market
https://www.delveinsight.com/report-store/tendonitis-market
Alpha-Antitrypsin Deficiency Market
https://www.delveinsight.com/report-store/alpha-antitrypsin-deficiency-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pulmonary Arterial Hypertension Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Acceleron, Liquidia Technologies, Pfizer, Merck, Insmed, Gossamer Bio, Johnson & Johnson, Nippon Shinyaku here
News-ID: 3150753 • Views: …
More Releases from DelveInsight Business Research LLP
Myelofibrosis Pipeline Report 2025 by DelveInsight: Key Insights into Clinical S …
DelveInsight's "Myelofibrosis Pipeline Insight" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Myelofibrosis…
Hemophilia Pipeline Landscape Report 2025: DelveInsight's Exclusive Report on Cu …
DelveInsight's "Hemophilia Pipeline Insight" report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia…
DelveInsight's NMIBC Pipeline 2025: Unveiling Drug Development Progress, Clinica …
DelveInsight's, "Non Muscle Invasive Bladder Cancer Pipeline Insight" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Non Muscle Invasive Bladder Cancer pipeline landscape. It covers the Non Muscle Invasive Bladder Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non Muscle Invasive Bladder Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive…
Hearing Loss Pipeline 2025 by DelveInsight: Exploring Novel Mechanisms of Action …
DelveInsight's "Hearing Loss Pipeline Insight" report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hthe earing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights!…
More Releases for Pulmonary
Chronic Pulmonary Aspergillosis Drugs Market - Revitalizing Lungs: Revolutionary …
Newark, New Castle, USA - new report, titled Chronic Pulmonary Aspergillosis Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Chronic Pulmonary Aspergillosis Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Chronic Pulmonary Aspergillosis Drugs market. The report offers…
Global Pulmonary Embolism Market Size & Trends
According to a new market research report published by Global Market Estimates, the Global Pulmonary Embolism Market is exhibited at USD 1.59 billion in 2023 and is projected to surpass USD 3.15 billion in 2028, anticipated to grow at a CAGR of 8.4% from 2023 to 2028.
The rapid increase in the prevalence of cancer, increasing investment for healthcare infrastructure and rising research and development activities, high disposable income, rising demand…
Global Pulmonary Arterial Hypertension Market Size
According to a new market research report published by Global Market Estimates, the Global Pulmonary Arterial Hypertension Market is projected to grow at a CAGR of 5.2% from 2022 to 2027.
Congenital heart diseases and other ailments such as HIV infection, chronic liver disease (cirrhosis), and connective tissue disorders (scleroderma, lupus, and others) are fueling market expansion.
Browse 153 Market Data Tables and 113 Figures spread through 185 Pages and in-depth TOC…
New Study: Pulmonary Drugs Market Report
The pulmonary drugs market is expected to witness unprecedented growth in the near future, thanks to large number of approvals from the FDA. The FDA approved a large number of pulmonary drugs for major illnesses like small-cell lung cancer, tuberculosis, and pneumonia over the past few years. Additionally, newly approved drugs also treat newly found diseases like obstructive sleep apnea. These approvals are in line with the recent trend of…
Pulmonary Drugs Market Forecast till 2025
Pulmonary Drugs Market – Boon for Diseased Lungs
Pulmonary drugs can treat wide range of conditions, which are included within the ambit of pulmonary diseases such as pneumonia, allergic rhinitis, pulmonary hypertension, and others. . Pulmonary drugs provide medications for all types of pulmonary diseases, which is expected to fuel market growth in near future. The World Health Organization (WHO) states that most respiratory diseases are preventable and can be treated…
Pulmonary Drug Delivery Devices Market: Demand for Pulmonary Drug Delivery Devic …
This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various pulmonary/respiratory drugs and/or drug-device combinations as well as new entrants planning to enter this market.
This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments…
